경，중등도의 인두염 및 인두편도염에서 Cefprozil의 임상효과와 안전성 검토

Background and Objective: Cefprozil is a new second generation oral cephalosporin, which has a longer half-life and efficacy in vitro against major respiratory pathogens, including moderately penicillin-resistant Streptococcus pneumoniae. The aim of the study is to investigate clinical efficacy and safety of cefprozil when administered once daily to patients with mild to moderate pharyngotonsillitis. Materials and Methods: A randomized, controlled study was conducted in 30 patients who were diagnosed as acute bacterial pharyngitis or pharyngotonsillitis. Cefprozil was given 500mg P.O. once daily for at least 5 consecutive days. Throat swab culture, CBC and blood chemistry were taken before and after the treatment. All patients were evaluated for clinical efficacy on the basis of the clincial, microbiological responses and side effects or toxicities. Results: The rate of satisfactory clinical response was 90%. Cefprozil was well tolerated and was associated with few drug-related clinical events. Conclusion: Because of its efficacy and once-daily dosing, cefprozil may prove to be an alternative to Currently available oral cephalosporins or beta-lactam inhibitors.